All In Biotech

Drug Trial Radar · NCT05673902

Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

An Open-Label Clinical Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Last checked: Nov 20, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

17

Actual

Start

Dec 11, 2020

Primary completion

Jan 2026

Study completion Jan 2026

Sponsor

Lead sponsor
R-Pharm International, LLCIndustry
Sponsor type
Industry
Collaborators
R-Pharm; Unimed Laboratories; Data Management 365; Exacte Labs LLC
First posted
Jan 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis who completed the main study CL04018068. The primary objective of the study is to evaluate the safety of RPH-104 80 mg once every 2 weeks in patients with idiopathic recurrent pericarditis who completed the main study.

Conditions

  • Idiopathic Recurrent Pericarditis

Interventions

  • RPH-104Biological

    solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred TermTime frame: Up to week 228
  2. Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred TermTime frame: Up to week 228
  3. Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI), by System Organ Class and Preferred TermTime frame: Up to week 228
  4. Incidence rate for serious adverse events (SAEs)Time frame: Up to week 228
  5. Incidence rate for adverse events of special Interest (AESI)Time frame: Up to week 228

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National medical research center named after V. A. Almazov

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.